EU/3/20/2390: Orphan designation for the treatment of idiopathic pericarditis

Rilonacept

Overview

On 6 January 2021, orphan designation EU/3/20/2390 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for rilonacept for the treatment of idiopathic pericarditis.

Key facts

Active substance
Rilonacept
Intented use
Treatment of idiopathic pericarditis
Orphan designation status
Positive
EU designation number
EU/3/20/2390
Date of designation
06/01/2021
Sponsor

Granzer Regulatory Consulting & Services
Kistlerhofstrasse 172c
81379 Munich
Germany
Tel: + 17814319100
E-mail: StudyInfo@kiniksa.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating